Teams from the Paris Public Hospitals (AP-HP), Pierre and Marie Curie University, Inserm and the CarThera company (which is hosted by the Brain and Spine Institute [ICM]), coordinated by Prof. Alexandre Carpentier, a neurosurgeon at Pitié-Salpêtrière Hospital, AP-HP, have successfully used ultrasound to temporarily permeabilise blood vessels in the brains of patients affected by recurrent malignant brain tumours. This innovative method allows increased delivery of treatments, including chemotherapeutic agents, to the brain, and represents hope for other brain pathologies. This work was published on 15 June in the international journal Science Translational Medicine.
Treatment of primary malignant brain tumours is currently based on a neurosurgical procedure followed by sessions of chemotherapy and/or radiotherapy. These treatments bring about disease remission for varying periods, depending on the patient. The blood-brain barrier (BBB), this particularly impermeable wall of vessels that limits the exposure of the neurons to toxic agents, restricts the entry and hence the delivery of treatments to the brain.
Given this observation, the respective teams led by Prof. Alexandre Carpentier and Dr Ahmed Idbaih, and the neuro-oncology group from Pitié-Salpêtrière Hospital, AP-HP, launched a phase 1/2a clinical trial in July 2014, sponsored by AP-HP, in patients with recurrent malignant brain tumours.
According to Prof. Alexandre Carpentier, “this innovative method offers hope for the
treatment of brain cancers, as well as other brain pathologies, such as, potentially, Alzheimer’s disease, where the existing drugs have difficulty in penetrating the brain. This technique must continue to undergo evaluation to allow its entry into routine clinical use in a few years.”
Researchers from Inserm, CNRS, Paris-Sud University, Gustave Roussy, and Institut Curie have identified a new agent in regulating PD-L1 gene expression: the eIF4F complex, which plays a role in controlling protein synthesis. ...
Over 3 million people in France are currently living with cancer or have recovered from it. While the number of new cases diagnosed each year continues to increase, the advances made in diagnosis and treatment have made it possible to push back mortality. The ...
Clinical trial of blood-brain barrier disruption AQ1 by pulsed ultrasound
Alexandre Carpentier,1,2* Michael Canney,3 Alexandre Vignot,3 Vincent Reina,1,2 Kevin Beccaria,1 Catherine Horodyckid,1 Carine Karachi,1,2 Delphine Leclercq,4 Cyril Lafon,5 Jean-Yves Chapelon,5 Laurent Capelle,1 Philippe Cornu,1,2 Marc Sanson,2,6,7,8,9 Khê Hoang-Xuan,2,6,7,8,9 Jean-Yves Delattre,2,6,7,8,9 Ahmed Idbaih2,6,7,8,9
1Assistance Publique–Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires La Pitié-Salpêtrière, Service de Neurochirurgie, F-75013 Paris, France.
2Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013 Paris, France.
3CarThera, Institut du Cerveau et de laMoelle épinière (ICM), Paris F-75013, France.
4AP-HP, Hôpitaux Universitaires La Pitié-Salpêtrière–Charles Foix, Service de Neuroradiologie, F-75013 Paris, France.
5INSERM, U1032, LabTau, Lyon F-69003, France.
6INSERM, U 1127, F-75013 Paris, France.
7CNRS, UMR 7225, F-75013, Paris, France.
8ICM, F-75013 Paris, France.
9AP-HP, Hôpitaux Universitaires La Pitié-Salpêtrière–Charles Foix, Service de Neurologie 2-Mazarin, F-75013 Paris, France. Science Translational Medicine